TY - JOUR
T1 - The N-formyl peptide receptors
T2 - contemporary roles in neuronal function and dysfunction
AU - Cussell, Peter J.G.
AU - Gomez Escalada, Margarita
AU - Milton, Nathaniel G.N.
AU - Paterson, Andrew W.J.
N1 - Funding Information:
Author contributions: PJGC, MGE, NGNM and AWJP wrote and critically reviewed the manuscript. All authors approved the final manuscript. Conflicts of interest: The authors declare the following competing financial interest(s): NGNM is named as the inventor on a UK patent held by the University of Roehampton for the use of kissorphin peptides to treat Alzheimer’s disease, Creutzfeldt-Jakob disease or diabetes mellitus (Publication Numbers: GB2493313 B); under the University of Roehampton rules he could benefit financially if the patent is commercially exploited. NGNM is also a shareholder and director of NeuroDelta Ltd (Company No. 06222473; http://www.neuro-delta.com). Financial support: This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. PJGC was supported by a Leeds Beckett University PhD studentship. Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication. Plagiarism check: Checked twice by iThenticate. Peer review: Externally peer reviewed. Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. Open peer reviewers: Farid Menaa, California Innovations Corporation, USA; Baruh Polis, Bar-Ilan University, Israel. Additional file: Open peer review reports 1 and 2.
Publisher Copyright:
© 20202 Wolters Kluwer Medknow Publications. All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - N-formyl peptide receptors (FPRs) were first identified upon phagocytic leukocytes, but more than four decades of research has unearthed a plethora of non-myeloid roles for this receptor family. FPRs are expressed within neuronal tissues and markedly in the central nervous system, where FPR interactions with endogenous ligands have been implicated in the pathophysiology of several neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, as well as neurological cancers such as neuroblastoma. Whilst the homeostatic function of FPRs in the nervous system is currently undefined, a variety of novel physiological roles for this receptor family in the neuronal context have been posited in both human and animal settings. Rapid developments in recent years have implicated FPRs in the process of neurogenesis and neuronal differentiation which, upon greater characterisation, could represent a novel pharmacological target for neuronal regeneration therapies that may be used in the treatment of brain/spinal cord injury, stroke and neurodegeneration. This review aims to summarize the recent progress made to determine the physiological role of FPRs in a neuronal setting, and to put forward a case for FPRs as a novel pharmacological target for conditions of the nervous system, and for their potential to open the door to novel neuronal regeneration therapies.
AB - N-formyl peptide receptors (FPRs) were first identified upon phagocytic leukocytes, but more than four decades of research has unearthed a plethora of non-myeloid roles for this receptor family. FPRs are expressed within neuronal tissues and markedly in the central nervous system, where FPR interactions with endogenous ligands have been implicated in the pathophysiology of several neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, as well as neurological cancers such as neuroblastoma. Whilst the homeostatic function of FPRs in the nervous system is currently undefined, a variety of novel physiological roles for this receptor family in the neuronal context have been posited in both human and animal settings. Rapid developments in recent years have implicated FPRs in the process of neurogenesis and neuronal differentiation which, upon greater characterisation, could represent a novel pharmacological target for neuronal regeneration therapies that may be used in the treatment of brain/spinal cord injury, stroke and neurodegeneration. This review aims to summarize the recent progress made to determine the physiological role of FPRs in a neuronal setting, and to put forward a case for FPRs as a novel pharmacological target for conditions of the nervous system, and for their potential to open the door to novel neuronal regeneration therapies.
KW - Alzheimer's disease
KW - formyl peptide receptor
KW - neural regeneration
KW - neuroblastoma
KW - neurodegeneration
KW - neuroinflammation
KW - neuronal differentiation
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85078124321&partnerID=8YFLogxK
U2 - 10.4103/1673-5374.272566
DO - 10.4103/1673-5374.272566
M3 - Review article
AN - SCOPUS:85078124321
SN - 1673-5374
VL - 15
SP - 1191
EP - 1198
JO - Neural Regeneration Research
JF - Neural Regeneration Research
IS - 7
ER -